These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
142 related articles for article (PubMed ID: 9293925)
1. Serum basic fibroblast growth factor and vascular endothelial growth factor in metastatic renal cell carcinoma treated with interferon alfa-2b. Vermeulen PB; Dirix LY; Martin M; Lemmens J; Van Oosterom AT J Natl Cancer Inst; 1997 Sep; 89(17):1316-7. PubMed ID: 9293925 [No Abstract] [Full Text] [Related]
2. Are angiogenic factors, cytokines, and soluble adhesion molecules prognostic factors in patients with renal cell carcinoma? Dosquet C; Coudert MC; Lepage E; Cabane J; Richard F Clin Cancer Res; 1997 Dec; 3(12 Pt 1):2451-8. PubMed ID: 9815646 [TBL] [Abstract][Full Text] [Related]
3. A phase II study of razoxane, an antiangiogenic topoisomerase II inhibitor, in renal cell cancer with assessment of potential surrogate markers of angiogenesis. Braybrooke JP; O'Byrne KJ; Propper DJ; Blann A; Saunders M; Dobbs N; Han C; Woodhull J; Mitchell K; Crew J; Smith K; Stephens R; Ganesan TS; Talbot DC; Harris AL Clin Cancer Res; 2000 Dec; 6(12):4697-704. PubMed ID: 11156222 [TBL] [Abstract][Full Text] [Related]
4. Serum concentrations of VEGF and b-FGF in renal cell, prostate and urinary bladder carcinomas. Edgren M; Lennernäs B; Larsson A; Nilsson S Anticancer Res; 1999; 19(1B):869-73. PubMed ID: 10216508 [TBL] [Abstract][Full Text] [Related]
5. Angiogenic factors: vascular endothelial growth factor (VEGF) and basic fibroblast growth factor (b-FGF) are not necessarily elevated in patients with advanced renal cell carcinoma. Edgren M; Lennernäs B; Larsson A; Kälkner KM Anticancer Res; 2001; 21(2B):1423-9. PubMed ID: 11396226 [TBL] [Abstract][Full Text] [Related]
6. Serum vascular endothelial growth factor load and interleukin-6 in cancer patients. O'Byrne KJ; Dobbs N; Harris AL Br J Cancer; 2000 Jun; 82(11):1895-6. PubMed ID: 10839310 [No Abstract] [Full Text] [Related]
7. Serum vascular endothelial growth factor is a candidate biomarker of renal cell carcinoma in hemodialysis patients. Ishizuka T; Hayashi T; Nakazawa H; Ito F; Nitta K; Horita S; Uchida K; Nihei H; Toma H Nephron; 2000 Jan; 84(1):83-4. PubMed ID: 10644915 [No Abstract] [Full Text] [Related]
13. Levels of angiogenic peptides in sera from patients with carcinoid tumours during alpha-interferon treatment. Nilsson A; Janson ET; Eriksson B; Larsson A Anticancer Res; 2001; 21(6A):4087-90. PubMed ID: 11911297 [TBL] [Abstract][Full Text] [Related]
14. Inhibitory effect on expression of angiogenic factors by antiangiogenic agents in renal cell carcinoma. Sasamura H; Takahashi A; Miyao N; Yanase M; Masumori N; Kitamura H; Itoh N; Tsukamoto T Br J Cancer; 2002 Mar; 86(5):768-73. PubMed ID: 11875741 [TBL] [Abstract][Full Text] [Related]
15. Serologic angiogenesis factors and microvascular density in renal cell carcinoma: two independent parameters. Wechsel HW; Feil G; Bichler KH; Beiter T; Gleichmann R Anticancer Res; 2000; 20(6D):5117-20. PubMed ID: 11326680 [TBL] [Abstract][Full Text] [Related]